


## WHAT IS CLAIMED IS

1. A triazole compound represented by the following formula:



wherein

R<sup>1</sup> is an alkyl group or a cycloalkyl group

wherein the alkyl group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, -CF<sub>3</sub>, -OH, -NH<sub>2</sub>, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R<sup>7</sup>)(R<sup>8</sup>), -N(R<sup>7</sup>)-CO-R<sup>8</sup>, an aryl group and a heteroaryl group

wherein R<sup>7</sup> and R<sup>8</sup> are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH<sub>2</sub>)<sub>n</sub>-OH, -N(R<sup>9</sup>)(R<sup>10</sup>), -CN, -NO<sub>2</sub>, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R<sup>11</sup>, an aryl group and a heteroaryl group

wherein n is 0-3, R<sup>9</sup> and R<sup>10</sup> are each independently a hydrogen atom, an alkyl group or -CO-alkyl, and R<sup>11</sup> is -OH, an alkoxy group, an alkyl group or -N(R<sup>12</sup>)(R<sup>13</sup>) wherein R<sup>12</sup> and R<sup>13</sup> are each

independently a hydrogen atom or an alkyl group;

Y is a cycloalkyl group or a heterocycloalkyl group wherein the cycloalkyl group and the heterocycloalkyl group are optionally substituted by 1 to 3 substituents each independently selected from a

halogen atom, a haloalkyl group, an alkyl group,  
 $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a  
 cycloalkyl group, an alkenyl group,  $-CO-R^{11}$ , an aryl  
 group and a heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as  
 5 defined above);

$Ar^1$  is an aryl group or a heteroaryl group;

$R^2$  and  $R^3$

are each independently a hydrogen atom, a halogen atom,  
 a haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  
 10  $-CN$ ,  $-NO_2$ , an alkoxy group, a cycloalkyl group, an  
 alkenyl group,  $-CO-R^{11}$ , an aryl group or a heteroaryl  
 group

wherein the aryl group and the heteroaryl group are  
 optionally substituted by 1 to 3 substituents each  
 15 independently selected from a halogen atom, a  
 haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  
 $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a cycloalkyl  
 group, an alkenyl group,  $-CO-R^{11}$ , an aryl group and a  
 heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined  
 20 above);

$Z$  is  $-(CH(R^{14}))_p-$ ,  $-(CH(R^{14}))_p-N(R^{16})-(CH(R^{15}))_q-$  or



wherein  $Y_1$  is a cycloalkyl group or a heterocycloalkyl  
 group


25 wherein the cycloalkyl group and the  
 heterocycloalkyl group are optionally substituted  
 by 1 to 3 substituents each independently selected  
 from a halogen atom, a haloalkyl group, an alkyl  
 group,  $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy  
 30 group, a cycloalkyl group, an alkenyl group,  $-CO-$   
 $R^{11}$ , an aryl group and a heteroaryl group ( $n$ ,  $R^9$ ,

$R^{10}$  and  $R^{11}$  are as defined above),  
 $p$  is 0-3,  $q$  is 0-3,  $R^{14}$  and  $R^{15}$  are each independently  
 a hydrogen atom, a halogen atom, a haloalkyl group,  
 an alkyl group,  $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an  
 5 alkoxy group, a cycloalkyl group, an alkenyl group,  
 $-CO-R^{11}$ , an aryl group or a heteroaryl group

wherein the aryl group and the heteroaryl group  
 are optionally substituted by 1 to 3 substituents  
 each independently selected from a halogen atom, a  
 10 haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  
 $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a  
 cycloalkyl group, an alkenyl group,  $-CO-R^{11}$ , an  
 aryl group and a heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  
 $R^{11}$  are as defined above), and

15  $R^{16}$  is a hydrogen atom, a haloalkyl group, an alkyl  
 group,  $-(CH_2)_n-OH$ ,  $-(CH_2)_n-CO-R^{11}$ , a cycloalkyl group,  
 an alkenyl group, an aryl group or a heteroaryl group  
 wherein the aryl group and the heteroaryl group  
 are optionally substituted by 1 to 3 substituents  
 20 each independently selected from a halogen atom, a  
 haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  
 $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a  
 cycloalkyl group, an alkenyl group,  $-CO-R^{11}$ , an  
 aryl group and a heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  
 25  $R^{11}$  are as defined above);

$Ar^2$  is an aryl group, a heteroaryl group or




wherein  $X_1$  is  $-(CH_2)_t-$  wherein  $t$  is 0-2,  $V_1$  is  $=CH-$  or  $=N-$ ,  
 and  $W_1$  is  $-C(R^{17})(R^{18})-$ ,  $-O-$ ,  $-S-$ ,  $-SO_2-$ ,  $-SO-$ ,  $-CO-$  or  
 30  $-N(R^{19})-$

wherein  $R^{17}$  and  $R^{18}$  are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group,  $-(CH_2)_r-OH$ ,  $-CO-R^{20}$ ,  $-N(R^{21})(R^{22})$  or  $-L_1-Ar^3$

5 wherein  $r$  is 0-3,  $R^{20}$  is  $-OH$ , an alkoxy group, an alkoxyalkyl group or  $-N(R^{23})(R^{24})$

wherein  $R^{23}$  and  $R^{24}$  are each independently a hydrogen atom, an alkyl group,  $-(CH_2)_s-OH$ , an alkoxyalkyl group, or in combination form



10 wherein  $s$  is 0-3,  $X_2$  is  $-O-$ ,  $-(CH_2)_t-$  or  $-N(R^{25})-$

wherein  $t$  is as defined above and  $R^{25}$  is a hydrogen atom,  $-CO-R^{26}$ ,  $-SO_2-R^{26}$  or  $-(CH_2)_u-Ar^4$

15 wherein  $R^{26}$  is an alkyl group, an alkoxy group,  $-NH$ -alkyl or  $-N(-alkyl)_2$ ,  $u$  is 0-3, and  $Ar^4$  is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  
 20  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a cycloalkyl group, an alkenyl group,  $-CO-R^{11}$ , an aryl group and a heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined above),

25  $L_1$  is  $-(CH_2)_v-$ ,  $-O-$  or  $-CO-$

wherein  $v$  is 0-3, and

$Ar^3$  is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a cycloalkyl group, an alkenyl group,

30

-CO-R<sup>11</sup>, an aryl group and a heteroaryl group (n, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined above), and

R<sup>21</sup> and R<sup>22</sup> are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-O-alkyl or -L<sub>1</sub>-Ar<sup>3</sup> (L<sub>1</sub> and Ar<sup>3</sup> are as defined above), and

R<sup>19</sup> is a hydrogen atom, -CO-R<sup>26</sup>, -SO<sub>2</sub>-R<sup>26</sup> or -(CH<sub>2</sub>)<sub>u</sub>-Ar<sup>4</sup> (R<sup>26</sup>, u and Ar<sup>4</sup> are as defined above); and

R<sup>4</sup> and R<sup>5</sup>

are each independently a hydrogen atom, a halogen atom, -OH, -NO<sub>2</sub>, -CN, an alkyl group, an alkoxy group, -CO-R<sup>27</sup>, -SO<sub>2</sub>-R<sup>27</sup>, -CO-N(R<sup>28</sup>)(R<sup>29</sup>) or -N(R<sup>30</sup>)(R<sup>31</sup>)

wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, -CF<sub>3</sub>, -OH, an alkoxy group, a haloalkoxy group, -N(R<sup>9</sup>)(R<sup>10</sup>), -CN, -NO<sub>2</sub>, a cycloalkyl group, an alkenyl group, -CO-R<sup>11</sup>, an aryl group and a heteroaryl group (R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined above),

wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH<sub>2</sub>)<sub>n</sub>-OH, -N(R<sup>9</sup>)(R<sup>10</sup>), -CN, -NO<sub>2</sub>, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R<sup>11</sup>, an aryl group and a heteroaryl group (n, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined above)


R<sup>27</sup> is -OH, an alkoxy group, an alkyl group, -NH<sub>2</sub>, -NH-alkyl or -N(-alkyl)<sub>2</sub>,

R<sup>28</sup> and R<sup>29</sup> are each independently a hydrogen atom, an alkyl group or -(CH<sub>2</sub>)<sub>w</sub>-R<sup>32</sup>,

wherein w is 0-3 and R<sup>32</sup> is -OH, -CF<sub>3</sub>, an alkoxy group, -CONH<sub>2</sub> or -N(R<sup>33</sup>)(R<sup>34</sup>)


wherein R<sup>33</sup> and R<sup>34</sup> are each independently a

hydrogen atom, an alkyl group, -CO-alkyl, or  
in combination form



(X<sub>2</sub> is as defined above)

or R<sup>28</sup> and R<sup>29</sup> in combination form



wherein X<sub>3</sub> is -CO-, -CH<sub>2</sub>- or -CH<sub>2</sub>-CH<sub>2</sub>-, X<sub>4</sub> is




-O-, -(CH<sub>2</sub>)<sub>t</sub>-, -N(R<sup>25</sup>)- or

wherein Y<sub>2</sub> is cycloalkyl or heterocycloalkyl  
and t and R<sup>25</sup> are as defined above, and R<sup>35</sup> and  
R<sup>36</sup> are each independently a hydrogen atom, a  
halogen atom, an alkyl group optionally  
substituted by -OH, -OH, -CN, -NO<sub>2</sub>, an alkoxy  
group, a cycloalkyl group, an alkenyl group,  
-CO-R<sup>37</sup>, -N(R<sup>38</sup>)(R<sup>39</sup>)

wherein R<sup>37</sup> is -OH, an alkoxy group, -NH<sub>2</sub>,

-NH-alkyl, -N(-alkyl)<sub>2</sub> or




(X<sub>2</sub> is  
as defined above)

wherein the alkyl group in -NH-alkyl  
and -N(-alkyl)<sub>2</sub> and the alkoxy group are  
optionally substituted by 1 to 5  
substituents each independently  
selected from a halogen atom, -CF<sub>3</sub>, -OH,  
an alkoxy group, a haloalkoxy group,  
-N(R<sup>9</sup>)(R<sup>10</sup>), -CN, -NO<sub>2</sub>, a cycloalkyl  
group, an alkenyl group,  
-CO-R<sup>11</sup>, an aryl group and a heteroaryl  
group (R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined  
above),

wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group,  $-(CH_2)_n-OH$ ,  $-N(R^9)(R^{10})$ ,  $-CN$ ,  $-NO_2$ , an alkoxy group, a cycloalkyl group, an alkenyl group,  $-CO-R^{11}$ , an aryl group and a heteroaryl group ( $n$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined above), and


$R^{38}$  and  $R^{39}$  are each independently a hydrogen atom, an alkyl group,  $-CO$ -alkyl or  $-CO-O$ -alkyl, and

$R^{30}$  and  $R^{31}$  are each independently a hydrogen atom, an alkyl group optionally substituted by  $-OH$ ,  $-SO_2$ -

$R^{40}$ ,  $-(CH_2)_x-CO-R^{41}$  or 

wherein  $x$  is 0-3,  $R^{40}$  is an alkyl group or  $-NH_2$ ,  $R^{41}$  is a hydrogen atom, an alkyl group optionally substituted by  $-OH$ ,  $-O$ , an alkoxy group, an alkoxyalkyl group or  $-(CH_2)_s-N(R^{42})(R^{43})$

wherein  $s$  is as defined above and  $R^{42}$  and  $R^{43}$  are each independently a hydrogen atom, an alkyl group,  $-OH$ , an alkoxy group, or in combination form



( $X_3$ ,  $X_4$ ,  $R^{35}$  and  $R^{36}$  are as defined above),

$V_2$  is  $=CH-$  or  $=N-$  and  $W_2$  is  $-C(R^{44})(R^{45})-$ ,  $-O-$  or  $-N(R^{46})-$

wherein  $R^{44}$  and  $R^{45}$  are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group,  $-(CH_2)_r-OH$ ,  $-CO-R^{47}$  or  $-N(R^{48})(R^{49})$


5 wherein  $r$  is as defined above,  $R^{47}$  is  $-OH$ , an alkoxy group, an alkoxyalkyl group,  $-N(R^{50})(R^{51})$

wherein  $R^{50}$  and  $R^{51}$  are each independently a hydrogen atom, an alkyl group,  $-(CH_2)_s-OH$  ( $s$  is as defined above) or an alkoxyalkyl group, and

10  $R^{48}$  and  $R^{49}$  are each independently a hydrogen atom, an alkyl group,  $-CO$ -alkyl or  $-CO-O$ -alkyl, and

15  $R^{46}$  is a hydrogen atom,  $-CO-R^{52}$  or  $-SO_2-R^{52}$  wherein  $R^{52}$  is an alkyl group, an alkoxy group,  $-NH$ -alkyl or  $-N(-alkyl)_2$  or

$R^{30}$  and  $R^{31}$  in combination form

20  ( $X_3$ ,  $X_4$ ,  $R^{35}$  and  $R^{36}$  are as defined above),

or

$R^4$  and  $R^5$  in combination may form  $-O$ -alkylene- $O$ -, a prodrug thereof or a pharmaceutically acceptable salt thereof.

25 2. The triazole compound of claim 1, wherein  $Z$  is  $-(CH(R^{14}))_p-$  and  $p$  is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof.


3. The triazole compound of claim 2, wherein  $Y$  is a  $C_{3-8}$  cycloalkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.



4. The triazole compound of claim 3, wherein Ar<sup>1</sup> is a phenyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 5
5. The triazole compound of claim 4, wherein R<sup>2</sup> and R<sup>3</sup> are each independently a halogen atom or a hydrogen atom, a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 10 6. The triazole compound of any of claims 1 to 5, wherein Ar<sup>2</sup> is a phenyl group, R<sup>4</sup> is a hydrogen atom, a halogen atom or an alkoxy group and R<sup>5</sup> is -CO-N(R<sup>28</sup>)(R<sup>29</sup>), a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 15 7. The triazole compound of claim 6, wherein R<sup>28</sup> and R<sup>29</sup> are each independently a hydrogen atom or an alkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.
8. The triazole compound of any of claims 1 to 5, wherein Ar<sup>2</sup> is a phenyl group, R<sup>4</sup> is a hydrogen atom or a halogen atom and R<sup>5</sup> is -N(R<sup>30</sup>)(R<sup>31</sup>) wherein R<sup>30</sup> is a hydrogen atom and R<sup>31</sup> is - (CH<sub>2</sub>)<sub>x</sub>-CO-R<sup>41</sup>, a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 20
9. The triazole compound of claim 8, wherein X is 0 and R<sup>41</sup> is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 25
10. The triazole compound of claim 8, wherein X is 0 and R<sup>41</sup> is - (CH<sub>2</sub>)<sub>s</sub>-N(R<sup>42</sup>)(R<sup>43</sup>), a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 30
11. The triazole compound of claim 10, wherein s is 0, R<sup>42</sup> is a

hydrogen atom and  $R^{43}$  is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

12. The triazole compound of any of claims 1 to 5, wherein  $Ar^2$  is a phenyl group,  $R^4$  is a hydrogen atom and  $R^5$  is  $-N(R^{30})(R^{31})$  wherein  $R^{30}$  and  $R^{31}$  are joined to form



and  $X_3$  is  $-CO-$ , a prodrug thereof or a pharmaceutically acceptable salt thereof.

13. The triazole compound of claim 12, wherein  $X_4$  is  $-O-$ , a prodrug thereof or a pharmaceutically acceptable salt thereof.

14. The triazole compound of claim 1, which is  
 3-chloro-4-[4-methyl-5-(1-phenyl-cyclopropyl)-4H-[1,2,4]triazol-3-yl]-benzamide,  
 {3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzoyl}morpholine,  
 3-chloro-N-methyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
 3-chloro-N,N-dimethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
 3-chloro-N-(2-hydroxy-ethyl)-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
 3-chloro-N-isopropyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
 {3-chloro-4-[4-methyl-5-(1-phenyl-cyclopropyl)-4H[1,2,4]triazol-3-yl]benzoyl}piperidine,  
 {3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H[1,2,4]triazol-3-yl]benzoyl}-(4-hydroxy)piperidine,  
 N-carbamoylmethyl-3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-

- 4H-[1,2,4]triazol-3-yl]benzamide,  
3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-N-(2,2,2-trifluoro-ethyl)-benzamide,  
N-(2-acetylamino)ethyl-3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
5 3-chloro-N-(2-methoxy)ethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
1-acetyl-(4-{3-Chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzoyl})piperazine,  
10 3-chloro-N-(2-dimethylamino)ethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-N-(2-morpholin-4-yl)ethylbenzamide,  
4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-3-methoxybenzamide,  
15 3-chloro-4-{4-methyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-N-methyl-4-{4-methyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
20 4-[4-isopropyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}benzamide,  
4-chloro-3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}benzamide,  
25 4-chloro-3-{5-[1-phenylcyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-4-[4-ethyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
30 3-chloro-4-{4-ethyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
3-[4-isopropyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,

- 3-{5-[1-(4-fluoro-phenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}benzamide,  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]phenyl}-1-morpholinecarboxamide,  
5 3-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-phenyl}-1,1-dimethylurea,  
{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-phenyl}urea,  
ethyl N-{3-Chloro-4-[4-methyl-5-(1-phenyl-cyclopropyl)-4H-  
10 [1,2,4]triazol-3-yl]-phenyl}-carbamate,  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]phenyl}-1-(4-methoxypiperidine)carboxamide,  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]phenyl}-1-(3-hydroxypiperidine)carboxamide,  
15 N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]phenyl}-1-(4-hydroxypiperidine)carboxamide,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-phenyl}-3-methoxyurea,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
20 [1,2,4]triazol-3-yl]phenyl}-3-hydroxy-3-methylurea,  
1-(3-chloro-4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
1-(4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
25 1-(3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
3-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-phenyl}oxazolidin-2-one,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
30 [1,2,4]triazol-3-yl]phenyl}imidazolidin-2-one,  
3-(3-chloro-4-{5-[1-(4-fluoro-phenyl)cyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-

- [1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(4-chloro-3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-  
[1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-  
5 [1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
methyl N-(4-chloro-3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-  
methyl-4H-[1,2,4]triazol-3-yl}phenyl)carbamate,  
a prodrug thereof or a pharmaceutically acceptable salt thereof.
- 10 15. The triazole compound of claim 1, which is  
3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]-benzamide,  
{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]benzoyl}morpholine,  
15 3-chloro-N-methyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]benzamide,  
3-chloro-N,N-dimethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]benzamide,  
3-chloro-N-(2-hydroxy-ethyl)-4-[4-methyl-5-(1-  
20 phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
3-chloro-N-isopropyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]benzamide,  
{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-  
4H[1,2,4]triazol-3-yl]benzoyl}piperidine,  
25 {3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H[1,2,4]triazol-  
3-yl]benzoyl}-(4-hydroxy)piperidine,  
N-carbamoylmethyl-3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-  
4H-[1,2,4]triazol-3-yl]benzamide,  
3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-  
30 3-yl]-N-(2,2,2-trifluoro-ethyl)-benzamide,  
N-(2-acetylamino)ethyl-3-chloro-4-[4-methyl-5-(1-  
phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]benzamide,  
3-chloro-N-(2-methoxy)ethyl-4-[4-methyl-5-(1-

- phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzamide,  
1-acetyl-(4-{3-Chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzoyl)piperazine,  
3-chloro-N-(2-dimethylamino)ethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-N-(2-morpholin-4-yl)ethylbenzamide,  
4-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-3-methoxybenzamide,  
3-chloro-4-{4-methyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-N-methyl-4-{4-methyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
4-[4-isopropyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzamide,  
4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}benzamide,  
4-chloro-3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}benzamide,  
4-chloro-3-{5-[1-phenylcyclopropyl]-4-methyl-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-4-[4-ethyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzamide,  
3-chloro-4-{4-ethyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-[1,2,4]triazol-3-yl}benzamide,  
3-[4-isopropyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl}benzamide,  
3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-[1,2,4]triazol-3-yl}benzamide,  
a prodrug thereof or a pharmaceutically acceptable salt thereof.

16. The triazole compound of claim 1, which is  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-

[1,2,4]triazol-3-yl}phenyl}-1-morpholinecarboxamide,  
3-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]-phenyl}-1,1-dimethylurea,  
{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
5 [1,2,4]triazol-3-yl]-phenyl}urea,  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl}phenyl}-1-(4-methoxypiperidine)carboxamide,  
N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl}phenyl}-1-(3-hydroxypiperidine)carboxamide,  
10 N-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl}phenyl}-1-(4-hydroxypiperidine)carboxamide,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]-phenyl}-3-methoxyurea,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
15 [1,2,4]triazol-3-yl}phenyl}-3-hydroxy-3-methylurea,  
1-(3-chloro-4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-  
[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
1-(4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-  
[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
20 1-(3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-  
[1,2,4]triazol-3-yl}phenyl)-3-methoxyurea,  
a prodrug thereof or a pharmaceutically acceptable salt thereof.

17. The triazole compound of claim 1, which is  
25 3-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl]-phenyl}oxazolidin-2-one,  
1-{3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-  
[1,2,4]triazol-3-yl}phenyl}imidazolidin-2-one,  
3-(3-chloro-4-{5-[1-(4-fluoro-phenyl)cyclopropyl]-4-methyl-4H-  
30 [1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(4-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-  
[1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(4-chloro-3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-

[1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
3-(3-{5-[1-(4-fluorophenyl)cyclopropyl]-4-isopropyl-4H-  
[1,2,4]triazol-3-yl}phenyl)oxazolidin-2-one,  
a prodrug thereof or a pharmaceutically acceptable salt thereof.

5

18. A pharmaceutical composition comprising the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10

19. An HSD1 (11beta-hydroxysteroid dehydrogenase 1) inhibitor comprising the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

15

20. A therapeutic or prophylactic drug of diabetes, which comprises the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

20

21. A therapeutic or prophylactic drug of obesity, which comprises the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

25

22. A therapeutic or prophylactic drug of metabolic syndrome, which comprises the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

30

23. A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the triazole compound of any of claims 1 to 17, a prodrug thereof



or a pharmaceutically acceptable salt thereof to a mammal.

24. A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the triazole  
5 compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

25. A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of  
10 the triazole compound of any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

26. The method of claim 23, wherein a different therapeutic  
15 drug of diabetes is used in combination.

27. The method of claim 26, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a  
20 sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an  $\alpha$ -glucosidase inhibitor and an insulin sensitizer.

28. The method of claim 27, wherein the different therapeutic  
25 drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and  
30 pioglitazone hydrochloride.

29. The method of claim 24, wherein a different therapeutic drug of diabetes is used in combination.

30. The method of claim 29, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a  
5 sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an  $\alpha$ -glucosidase inhibitor and an insulin sensitizer.

31. The method of claim 30, wherein the different therapeutic  
10 drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and  
15 pioglitazone hydrochloride.

32. The method of claim 25, wherein a different therapeutic drug of diabetes is used in combination.

20 33. The method of claim 32, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an  $\alpha$ -glucosidase inhibitor and an insulin  
25 sensitizer.

34. The method of claim 33, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide,  
30 tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

35. The method of claim 23, wherein a different therapeutic drug of obesity is used in combination.

5 36. The method of claim 35, wherein the different therapeutic drug of obesity is Mazindol.

37. The method of claim 24, wherein a different therapeutic drug of obesity is used in combination.

10

38. The method of claim 37, wherein the different therapeutic drug of obesity is Mazindol.

39. The method of claim 25, wherein a different therapeutic  
15 drug of obesity is used in combination.

40. The method of claim 39, wherein the different therapeutic drug of obesity is Mazindol.